SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mark A. Stang who wrote (3053)12/5/1997 8:17:00 AM
From: Edderd  Read Replies (2) of 23519
 
Mark,
At the last AUA meeeting the "product" was presented. It consists of lyophilized (?freeze dried) PGe which is instantly activated by a simple solution and is administered into the urethra, PAINLESSLY. It has a shelf life of over 3 yrs. The major drawback of MUSE is that many people get urethral burning enough to stop using the drug. It is really a definite threat to MUSE and would probably replace it unless the problem of burning is stopped. I know Vivus is working on this problem. Something to worry about.
Ed
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News